Figure 8.

miR-665-3p antagomir activates AMPKα via increasing FNDC5 expression. (a) Graphic representation of the miR-665-3p binding motifs within the 3ʹ-UTR of FNDC5. (b-c) The mRNA and protein levels of FNDC5 in the liver from HFD mice. (d) The levels of hepatic irisin detected by a commercial ELISA kit. (e) Relative luciferase activity of the reporter constructs containing either WT or TRU 3ʹ-UTR of FNDC5 after treatment with miR-665-3p agomir. (f) The mRNA levels of FNDC5 in the liver from HFD mice treated with shFNDC5 or shRNA. (g) The levels of AMPKα phosphorylation. (h) Hepatic hydroxyproline levels. (i) Serum ALT and AST levels. All results were expressed as the means ± standard deviations, n = 6 for each group, and *P < 0.05 was considered statistically significant.